Emma Walmsley, GSK CEO
July 26, 2023 03:33 PM EDT
Pharma
Marketing

GSK bull­ish on RSV vac­cine bat­tle against Pfiz­er, ships first Arexvy dose

Reynald Castañeda

Deputy Editor

Amber Tong

Senior Editor

GSK is bull­ish about the mar­ket prospects for its RSV vac­cine Arexvy in old­er adults.

The Big Phar­ma has al­ready shipped its first dos­es to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

A service from the Financial Times